This week, we’re covering the U.S. Food and Drug Administration (FDA) approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we’ll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.